Quick Answer
INTEGRA LIFESCIENCES HOLDINGS CORP reported Cash and Equivalents of $235.05 million for fiscal year 2025.
INTEGRA LIFESCIENCES HOLDINGS CORP Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $235.05M | -4.6% |
| 2024 | $246.38M | -10.9% |
| 2023 | $276.40M | -39.5% |
| 2022 | $456.66M | -11.1% |
| 2021 | $513.45M | +9.2% |
| 2020 | $470.17M | +136.4% |
| 2019 | $198.91M | +43.3% |
| 2018 | $138.84M | -20.6% |
| 2017 | $174.94M | +71.4% |
| 2016 | $102.06M | +112.0% |
| 2015 | $48.13M | -32.9% |
| 2014 | $71.73M | -40.5% |
| 2013 | $120.61M | +24.4% |
| 2012 | $96.94M | -3.8% |
| 2011 | $100.81M | -21.7% |
| 2010 | $128.76M | +79.1% |
| 2009 | $71.89M | -60.8% |
| 2008 | $183.55M | +220.1% |
| 2007 | $57.34M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $232.19M | +7.9% | +6.5% |
| June 30, 2025 | $217.91M | +1.2% | -8.9% |
| March 31, 2025 | $239.10M | -59.6% | -3.0% |
| December 31, 2024 | $246.38M | -10.9% | +14.5% |
| September 30, 2024 | $215.16M | -21.4% | -0.0% |
| June 30, 2024 | $215.24M | -30.4% | -63.6% |
| March 31, 2024 | $591.91M | +92.6% | +114.1% |
| December 31, 2023 | $276.40M | -39.5% | +1.0% |
- INTEGRA LIFESCIENCES HOLDINGS CORP showed a decrease of -4.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2007–2025 period, INTEGRA LIFESCIENCES HOLDINGS CORP’s cash and equivalents has grown by 309.9% (from $57.34 million to $235.05 million).
- The most recent figure is from INTEGRA LIFESCIENCES HOLDINGS CORP’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: